How Medicare's 2026 Drug Price Changes Will Affect You

If you’re on Medicare, you’ve likely heard whispers of big changes coming to prescription drug costs. These aren’t just minor adjustments. Thanks to new legislation, significant updates are rolling out, with major impacts starting in 2026 that could directly affect the price you pay for some of the most common medications. This guide breaks down exactly what’s changing, which drugs are affected first, and what it means for your wallet.

The Reason for the Changes: The Inflation Reduction Act

The driving force behind these updates is the Inflation Reduction Act of 2022. This law gave Medicare a powerful new tool it never had before: the ability to directly negotiate the prices of certain high-cost prescription drugs with manufacturers. For decades, Medicare was legally prohibited from doing this, but that has now changed.

The goal is to lower out-of-pocket spending for seniors and reduce overall costs for the Medicare program. The process is gradual, with new drugs being selected for negotiation each year. The very first negotiated prices for the initial group of selected drugs will take effect on January 1, 2026. This is a landmark shift in how Medicare Part D (the prescription drug benefit) operates.

The First 10 Drugs Targeted for Lower Prices in 2026

The ad you clicked mentioned that these updates could affect common prescriptions, and that is precisely the case. The Centers for Medicare & Medicaid Services (CMS) identified the first 10 drugs covered under Part D for price negotiation. These medications were selected because they account for a significant portion of Medicare spending and have been on the market for years without generic or biosimilar competition.

If you take any of the following medications, you may see lower costs for them beginning in 2026.

Here is the official list of the first 10 drugs:

  • Eliquis: A very common blood thinner used to prevent blood clots and reduce the risk of stroke in people with atrial fibrillation.
  • Jardiance: A popular medication used to control blood sugar in adults with type 2 diabetes and to reduce the risk of cardiovascular events.
  • Xarelto: Another widely used blood thinner that helps prevent blood clots in various conditions, similar to Eliquis.
  • Januvia: An oral medication that helps improve blood sugar control in adults with type 2 diabetes.
  • Farxiga: Used to treat type 2 diabetes, heart failure, and chronic kidney disease.
  • Entresto: A combination medication prescribed for certain types of heart failure to help reduce the risk of cardiovascular death and hospitalization.
  • Enbrel: An injectable biologic drug used to treat several autoimmune conditions, including rheumatoid arthritis and psoriasis.
  • Imbruvica: A targeted therapy drug used to treat certain types of blood cancers, such as mantle cell lymphoma and chronic lymphocytic leukemia.
  • Stelara: A prescription medicine used to treat conditions like plaque psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis.
  • Fiasp; Fiasp FlexTouch; Fiasp PenFill; Novolog; Novolog FlexPen; Novolog PenFill: These are different brand names and delivery forms for insulin aspart, a rapid-acting insulin used to manage blood sugar in people with diabetes.

The new, lower prices for these specific drugs will be announced by September 1, 2024, and will become effective for all Medicare beneficiaries on January 1, 2026.

More Than Just 10 Drugs: Other Big Changes to Your Costs

While the negotiation of specific drug prices is a major headline, the Inflation Reduction Act introduced other sweeping changes that provide even broader financial protection for all Medicare beneficiaries. Some of these changes are already in effect or will be before 2026.

A New Cap on Out-of-Pocket Drug Costs

This is perhaps the most significant change for those with very high prescription costs. Starting in 2025, your annual out-of-pocket spending on Part D prescription drugs will be capped at $2,000.

Previously, there was no hard cap. Once you reached the “catastrophic coverage” phase, you were still responsible for 5% of the cost of your drugs, which could add up to thousands of dollars for people taking expensive specialty medications. This new $2,000 cap means that once you have spent that amount on covered drugs in a year, you will pay $0 for the rest of the year. This provides a crucial financial safety net.

Spreading Out Your Payments with “Smoothing”

Also beginning in 2025, a new program called the Medicare Prescription Payment Plan will be available. This is often referred to as “smoothing.” If you are facing high upfront costs at the beginning of the year, you can elect to spread your out-of-pocket payments into monthly installments throughout the year, rather than paying them all at once at the pharmacy counter. This can make budgeting much more predictable and manageable.

Capping the Cost of Insulin

The law has already implemented a significant benefit for people with diabetes. As of 2023, the out-of-pocket cost for a one-month supply of any Part D-covered insulin product is capped at $35. This provides immediate and substantial relief for millions of Medicare beneficiaries.

Another immediate benefit that started in 2023 is that all adult vaccines recommended by the Advisory Committee on Immunization Practices (ACIP), such as the shingles vaccine (Shingrix), are now available with no deductible or cost-sharing for people with Medicare Part D.

What to Expect in the Coming Years

The changes starting in 2026 are just the beginning. The Medicare Drug Price Negotiation Program will continue to expand.

  • For 2027: An additional 15 Part D drugs will be selected for negotiation.
  • For 2028: Another 15 drugs, including some covered by Part B (drugs administered in a doctor’s office), will be chosen.
  • For 2029 and beyond: 20 new drugs will be selected for negotiation each year.

This ongoing process means that over time, more and more of the most expensive drugs will have their prices lowered, bringing widespread relief to seniors across the country.

Frequently Asked Questions

Do I need to do anything to get the lower prices for the negotiated drugs? No. If you are prescribed one of the drugs on the negotiation list, the new, lower price will be automatically reflected in what you pay at the pharmacy starting in 2026, as long as your Part D plan covers that drug.

How will I know what the new negotiated price is? CMS will publish the “maximum fair prices” for the first 10 drugs by September 1, 2024. This information will be publicly available, and drug plan providers will use these prices when setting their formularies and costs for the 2026 plan year.

Will my specific Part D plan still matter? Yes, absolutely. While the negotiated price sets a new baseline, your specific monthly premium, deductible, and copays will still depend on the Part D plan you choose during Open Enrollment. It remains crucial to compare plans each year to find the one that best covers all of your medications at the lowest total cost.